<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01932372</url>
  </required_header>
  <id_info>
    <org_study_id>A3921194</org_study_id>
    <nct_id>NCT01932372</nct_id>
  </id_info>
  <brief_title>Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis</brief_title>
  <official_title>Tofacitinib Special Investigation Of Xeljanz Tablets 5mg. (Regulatory Post Marketing Commitment Plan)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this Surveillance is to verify the following subject matters concerning
      Tofacitinib (Xeljanz) under general practice.

      1) Occurrence of adverse reactions, factors that may potentially affect safety and efficacy
      2） Long-term safety (particularly, malignant tumors and serious infections) and efficacy

      Occurrences of malignant tumors and serious infections will be compared with a control group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All the patients whom an investigator prescribes the Xeljanz or Standard of Care for
      rheumatoid arthritis should be registered consecutively until the number of subjects reaches
      target number in order to extract patients enrolled into the investigation at random.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 26, 2013</start_date>
  <completion_date type="Anticipated">January 26, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 26, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Activity Score Based on 28-joints Count (DAS28)</measure>
    <time_frame>24 months</time_frame>
    <description>DAS28 calculated from the number of swollen joints (SJC) and painful joints (PJC) using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and patient's global assessment (PGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 ≤3.2 = low disease activity, DAS28 &gt;3.2 to 5.1 = moderate to high disease activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment-Related Adverse Events (AEs) or Serious Adverse Events (SAEs)</measure>
    <time_frame>36 months</time_frame>
    <description>An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">6000</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Tofacitinib (Xeljanz)</arm_group_label>
    <description>Tablets 5 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <description>Standard of Care for Rheumatoid Arthritis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tofacitinib (Xeljanz)</intervention_name>
    <description>5 mg Tablet BID</description>
    <arm_group_label>Tofacitinib (Xeljanz)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc</intervention_name>
    <description>Etanercept: 10 to 25 mg twice weekly, or 25 to 50 mg once weekly</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with moderately to severely active rheumatoid arthritis who have had an
        inadequate response or intolerance to over 8 mg Methotrexate for 3 months treatment.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients receiving Tofacitinib (Xeljanz)

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921194&amp;StudyName=Tofacitinib%20%28Xeljanz%29%20Special%20Investigation%20for%20Rheumatoid%20Arthritis</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2013</study_first_submitted>
  <study_first_submitted_qc>August 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2013</study_first_posted>
  <last_update_submitted>February 7, 2018</last_update_submitted>
  <last_update_submitted_qc>February 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Good Post Marketing Study Practice</keyword>
  <keyword>Tofacitinib</keyword>
  <keyword>Xeljanz</keyword>
  <keyword>Regulatory Post Marketing Commitment Plan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Antirheumatic Agents</mesh_term>
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

